干扰素α-2b辅助治疗高危切除后皮肤黑色素瘤:东部肿瘤协作组EST 1684试验
东部肿瘤协作组(ECOG)在287例高危切除后皮肤黑色素瘤患者中开展随机对照试验,比较干扰素α-2b(IFN α-2b)与观察。中位随访6.9年,IFN α-2b组无复发生存(单侧P=0.0023)和总生存(单侧P=0.0237)均显著延长,淋巴结阳性分层获益最大,毒性多需调整剂量但多数可完成≥80%计划剂量。
要点
- IFN α-2b延长高危切除后黑色素瘤患者无复发生存(单侧P=0.0023)和总生存(单侧P=0.0237)。
- 中位无病生存从1年延长至1.7年,中位总生存从2.8年延长至3.8年。
- 持续无病生存比例从26%提高至37%,绝对改善42%。
核心结论
- IFN α-2b延长高危切除后黑色素瘤患者的无复发生存间期和总生存。
- IFN α-2b是首个在随机对照试验中显示高危黑色素瘤患者无复发生存和总生存显著获益的药物。
研究设计与样本
- 东部肿瘤协作组(ECOG)开展的随机对照研究,共纳入287例高危切除后皮肤黑色素瘤患者。
- 干预为IFN α-2b(先灵葆雅,肯尼沃思,新泽西州)最大耐受剂量20 MU/m²/d静脉注射1个月,随后10 MU/m²每周三次皮下注射48周,对照为观察。
主要发现
- 中位随访6.9年,IFN α-2b组无复发生存显著延长(单侧P=0.0023),总生存显著延长(单侧P=0.0237)。
- 治疗对复发率的影响在治疗间期早期最明显。
- 按肿瘤负荷和是否存在微观不可触及及可触及区域淋巴结转移分层分析,IFN α-2b的获益在淋巴结阳性分层中最大。
- IFN α-2b毒性导致多数患者需调整剂量,但多数患者在静脉注射阶段和超过3个月的皮下维持治疗期间可接受≥80%计划剂量。
- 治疗第4个月后因毒性停药不常见。
关键数值与推荐
- 中位无病生存从1年延长至1.7年,中位总生存从2.8年延长至3.8年。
- 持续无病生存患者比例从26%提高至37%,绝对改善42%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic melanoma and on this basis has been evaluated as an adjuvant therapy following surgery for deep primary (T4) or regionally metastatic (N1) melanoma. METHODS: A randomized controlled study of IFN alpha-2b (Schering-Plough, Kenilworth, NJ) administered at maximum-tolerated doses of 20 MU/m2/d intravenously (i.v.) for 1 month and 10 MU/m2 three times per week subcutaneously (SC) for 48 weeks versus observation, was conducted by the Eastern Cooperative Oncology Group (ECOG) in 287 patients. RESULTS: A significant prolongation of relapse-free survival (P = .0023, one-sided) and prolongation of overall survival (P = .0237, one-sided) was observed with IFN alpha-2b therapy in this trial, which is now mature with a median follow-up time of 6.9 years. The impact of treatment on relapse rate is most pronounced early during the treatment interval. The overall benefit of treatment in this trial was analyzed stratified by tumor burden and the presence or absence of microscopic nonpalpable and palpable regional lymph node metastasis. The benefit of therapy with IFN alpha-2b was greatest among node-positive strata. Toxicity of IFN alpha-2b required dose modification in the majority of patients, but treatment at > or = 80% of the scheduled dose was feasible in the majority of patients through the IV phase of treatment, and for more than 3 months of SC maintenance therapy. Discontinuation of treatment due to toxicity was infrequent after the fourth month of therapy. CONCLUSION: IFN alpha-2b prolongs the relapse-free interval and overall survival of high-risk resected melanoma patients. The increment in median disease-free survival (from 1 to 1.7 years) and overall survival (from 2.8 to 3.8 years) that results from this therapy is associated with a 42% improvement in the fraction of patients who are continuously disease-free after treatment with IFN (from 26% to 37%) in comparison to observation. IFN alpha-2b is the first agent to show a significant benefit in relapse-free and overall survival of high-risk melanoma patients in a randomized controlled trial.
引用
- Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 2023. PMID: 36649675. doi:10.1200/JCO.22.02264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。